IP Library Granted Patent US 7,041,454
Granted Patent B2
US 7,041,454 · App. 10/376,893 · Granted May 9, 2006

Genomic sequence of the purH gene and purH-related biallelic markers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,041,454
App. No.
10/376,893
Granted
May 9, 2006
Kind
B2
Abstract

The invention concerns the genomic sequence of the purH gene. The invention also concerns biallelic markers of a purH gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.

Claims (9)

1. A method of determining whether an individual is at an increased risk for developing prostate cancer comprising the steps of:

(a) obtaining a biological sample comprising a nucleic acid from said individual;

(b) determining the identity of a biallelic marker at position 22906 of SEQ ID NO: 1 and 31250 of SEQ ID NO: 1 within said biological sample; and

(c) evaluating whether an individual is at increased risk of prostate cancer; wherein the presence of both an A at position 22906 of SEQ ID NO: 1 and a G at position 31250 of SEQ ID NO: 1 is indicative of an increased risk for developing prostate cancer.

2. The method according to claim 1 , further comprising the step of amplifying a portion of said purH gene comprising said biallelic marker prior to determining the identity of said nucleotide.

3. The method according to claim 2 , wherein said amplifying is performed by PCR.

4. The method according to claim 1 , wherein said nucleotide is determined by performing a microsequencing assay.

5. The method according to claim 1 , wherein said nucleotide is determined by performing a hybridization assay.

6. The method according to claim 1 , wherein said nucleotide is determined by performing a sequencing assay.

Assignments (3)
CHANGE OF NAME Recorded Aug 3, 2005
From: GENSET S.A.
To: SERONO GENETICS INSTITUTE S.A.
Reel/Frame 016348/0865 →
CHANGE OF ASSIGEE ADDRESS Recorded Aug 25, 2003
From: GENSET S.A.
To: GENSET S.A.
Reel/Frame 013907/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2003
From: BLUMENFELD, MARTA; CHUMAKOV, ILYA; BOUGUELERET, LYDIE; COHEN-AKENINE, ANNICK
To: GENESET, S.A.
Reel/Frame 013883/0845 →